Saturday, October 29, 2016 9:18:15 AM
I truly don't hope an acquisition will materialize. $10-15 right now would be a disappointment.
A partnership deal would make sense and be beneficial. FDA approval for EPP seems like a shoe in and after the pre-NDA meeting in November the Vitiligo program should get more attention. Clinuvel has stated numerous times that the EPP and Vitiligo programs are intertwined in the US, most likely meaning that a majority of the data package with regard to safety etc. will be the groundwork in a forthcoming NDA for Vitiligo. Therefore, the submission of an NDA for EPP at a stage where everyone anticipates the FDA to approve also constitutes a good opportunity for a partner to come in and take the lead on Vitiligo.
The chairman has been touting an enlargement of the "group" lately and I believe that a such is imminent. The question is which form it will take.
The recent rise in share price is nice but does in no way reflect the true value of this company. A buyout would be tragic. A partner would be welcomed.
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM